AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28450428 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As Team intervention
Number of subjects: 28
Study 26254948 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered self-management intervention (T-SM) (n=75)
Number of subjects: 163
Study 26254948 — intervention group
Group type: COMPARATOR
Intervention: Telephone-delivered MS education intervention (T-ED) (n=88)
Number of subjects: 163
Study 26254948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study 22981362 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse coloplasty (TCP)
Number of subjects: 106
Study 22981362 — intervention group
Group type: COMPARATOR
Intervention: Colonic J-pouch (CJP)
Number of subjects: 106
Study 21358011 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (probiotic plus prebiotic)
Number of subjects: 41
Study 21358011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21358011 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 41
Study 21358011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 41
Study 18300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse 3 times a day for 3 weeks (Arm A)
Number of subjects: 225
Study 18300265 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo (normal saline) with the same dose and frequency (Arm B)
Number of subjects: 225
Study 18300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with crushed ice for 45 minutes during chemotherapy (Arm C)
Number of subjects: 225
Study 17213254 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 254
Study 17213254 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 254
Study 17213254 — intervention group
Group type: EXPERIMENTAL
Intervention: RS
Number of subjects: 254
Study 17213254 — intervention group
Group type: COMPARATOR
Intervention: Control group of RCT
Number of subjects: 254
Study 15633323 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 170
Study 15633323 — intervention group
Group type: COMPARATOR
Intervention: Injection anesthesia (lidocaine 2% adrenaline)
Number of subjects: 170
Study 15633323 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic gel
Number of subjects: 170
Study 15633323 — intervention group
Group type: COMPARATOR
Intervention: Injection anesthesia
Number of subjects: 170
Study 11734708 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime for 3 days
Number of subjects: 80
Study 11734708 — intervention group
Group type: COMPARATOR
Intervention: Topical polymyxin‐bacitracin for 7 days
Number of subjects: 80
Study 11734708 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime
Number of subjects: 80
Study 11734708 — intervention group
Group type: COMPARATOR
Intervention: Topical polymyxin‐bacitracin
Number of subjects: 80
Study 9222674 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal saline injection
Number of subjects: 57
Study 9222674 — intervention group
Group type: COMPARATOR
Intervention: No submucosal saline injection
Number of subjects: 57
Study 8109212 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser photocoagulation
Number of subjects: 0
Study 8109212 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon blue-green laser photocoagulation
Number of subjects: 0
Study 8109212 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 0
Study 8109212 — intervention group
Group type: COMPARATOR
Intervention: Argon green and argon blue-green lasers
Number of subjects: 0
Study 8109212 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon blue-green laser
Number of subjects: 0
Study 3651264 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course radiation therapy with a 3-week rest interval
Number of subjects: 0
Study 3651264 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiation therapy with a 5-week rest interval
Number of subjects: 0
Study 30892640 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 534
Study 30892640 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 534
Study 27908492 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC nailing (Group A)
Number of subjects: 87
Study 27908492 — intervention group
Group type: COMPARATOR
Intervention: ORIF (Group B)
Number of subjects: 87
Study 26021563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative brief electrical stimulation (BES) for 60 min continuously at 20 Hz, 3 to 5 V, in 100‐msec pulses.
Number of subjects: 0
Study 26021563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative brief electrical stimulation (BES)
Number of subjects: 0
Study 26021563 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24364800 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention, 4 sessions
Number of subjects: 143
Study 24364800 — intervention group
Group type: COMPARATOR
Intervention: Content-matched education, 4 sessions
Number of subjects: 143
Study 21545527 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise program (endurance and activity of daily living training, twice a day)
Number of subjects: 47
Study 21545527 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy program (once a day)
Number of subjects: 47
Study 19702817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Self-Management Program (CDSMP)
Number of subjects: 0
Study 17350452 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA) 24 microg/kg/h for 96 h
Number of subjects: 477
Study 17350452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 17350452 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 477
Study 15142004 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week training program
Number of subjects: 25
Study 15142004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study 11468940 — intervention group
Group type: EXPERIMENTAL
Intervention: Wald's approximation to the likelihood ratio test (LRT) statistic
Number of subjects: 0
Study 11468940 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model fit of k covariate parameters
Number of subjects: 0
Study 11468940 — intervention group
Group type: EXPERIMENTAL
Intervention: Model selection and validation
Number of subjects: 0
Study 9737496 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 15
Study 9737496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7635025 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation around the time of conception and in early pregnancy
Number of subjects: 2000
Study 3117400 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) group, intravesical instillation with 50 mg ADM dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Number of subjects: 103
Study 3117400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) group, intravesical instillation with 30 mg MMC dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Number of subjects: 103
Study 3117400 — intervention group
Group type: COMPARATOR
Intervention: Control group, transurethral resection or transurethral coagulation alone; no drug intervention.
Number of subjects: 103
Study 31609926 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate capsules at a dose of 45 mg (low-dose) daily for 16 weeks
Number of subjects: 52
Study 31609926 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate capsules at a dose of 90 mg (high-dose) daily for 16 weeks
Number of subjects: 52
Study 28919811 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 456
Study 28919811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 25133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Early provision of normal test results immediately following testing
Number of subjects: 51
Study 25133827 — intervention group
Group type: COMPARATOR
Intervention: Results provided 4 weeks later
Number of subjects: 51
Study 23392882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2.0 g TAU and 3.2 g BCAA, thrice a day, for 2 weeks prior to and 4 days after exercise
Number of subjects: 36
Study 23392882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23392882 — intervention group
Group type: COMPARATOR
Intervention: BCAA alone (3.2 g)
Number of subjects: 36
Study 23392882 — intervention group
Group type: COMPARATOR
Intervention: TAU alone (2.0 g)
Number of subjects: 36
Study 21843919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour resection plus tamoxifen (T + T)
Number of subjects: 71
Study 19392869 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) / Mercaptopurine (MP)
Number of subjects: 1632
Study 17244641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine post-fibrinolysis angioplasty
Number of subjects: 212
Study 17244641 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 212
Study 12622759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation (10 LGG)
Number of subjects: 20
Study 12622759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 placebo)
Number of subjects: 20
Study 11137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (170 microg/day)
Number of subjects: 367
Study 11137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (350 microg/day)
Number of subjects: 367
Study 11137327 — intervention group
Group type: COMPARATOR
Intervention: Transdermal hormone replacement therapy with E2 and sequential oral progestogen
Number of subjects: 367
Study 11137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with lower dose of NETA (170 microg/day)
Number of subjects: 367
Study 11137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with higher dose of NETA (350 microg/day)
Number of subjects: 367
Study 11137327 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 367
Study 8959465 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine (antidepressant)
Number of subjects: 0
Study 8959465 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or other antidepressants not specified)
Number of subjects: 0
Study 1549951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with reminders and recall letter
Number of subjects: 546
Study 1549951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with reminders only
Number of subjects: 546
Study 1549951 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 546
Study 4025772 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia with bupivacaine 0.75%
Number of subjects: 40
Study 4025772 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with diazepam, fentanly and N2O/O2
Number of subjects: 40
Study 30574790 — intervention group
Group type: COMPARATOR
Intervention: Standard dose enoxaparin (1 mg/kg)
Number of subjects: 62
Study 30574790 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose enoxaparin (0.8 mg/kg)
Number of subjects: 62
Study 30194765 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Number of subjects: 60
Study 30194765 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Number of subjects: 60
Study 25933911 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics treatment
Number of subjects: 362
Study 25933911 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study 25495109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity collaborative care program
Number of subjects: 0
Study 25495109 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 22750451 — intervention group
Group type: COMPARATOR
Intervention: SGA infants
Number of subjects: 139
Study 20056901 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 21
Study 18281656 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg PO bid
Number of subjects: 134
Study 18281656 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg PO qid
Number of subjects: 134
Study 18281656 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib and Zileuton at the same doses
Number of subjects: 134
Study 18281656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 134
Study 15963058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose testosterone (Te) supplementation
Number of subjects: 15
Study 15963058 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose testosterone (Te) supplementation
Number of subjects: 15
Study 15963058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 15
Study 12676601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combustion particles (1.0 mg/m3) followed by allergen challenge
Number of subjects: 8
Study 12676601 — intervention group
Group type: COMPARATOR
Intervention: Combustion particles (1.0 mg/m3)
Number of subjects: 8
Study 12676601 — intervention group
Group type: COMPARATOR
Intervention: Clean air followed by allergen
Number of subjects: 8
Study 12676601 — intervention group
Group type: COMPARATOR
Intervention: Particles followed by no allergen
Number of subjects: 8
Study 10760528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclamptic women
Number of subjects: 75
Study 8991550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight pulse oximetry (PO)
Number of subjects: 20
Study 1424429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan and carbidopa
Number of subjects: 31
Study 1424429 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa and carbidopa
Number of subjects: 31
Study 1424429 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 3008313 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. applicable CMV-hyperimmunoglobulin administered prior to transplant
Number of subjects: 83
Study 3008313 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 83
Study 31142032 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRI‐SUMAN intervention
Number of subjects: 379
Study 29921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based digital images for cervical cancer screening
Number of subjects: 125
Study 29921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by gynecologists (45 total, with varying experience)
Number of subjects: 125
Study 26340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 ppm F) at pH 4.5
Number of subjects: 22
Study 26340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 ppm F) at pH 4.5
Number of subjects: 22
Study 26340981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm F) at pH 4.5
Number of subjects: 22
Study 26340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 ppm F) at pH 7.0
Number of subjects: 22
Study 26340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 ppm F) at pH 7.0
Number of subjects: 22
Study 26340981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm F) at pH 7.0
Number of subjects: 22
Study 25239590 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (0.04 mg/kg oral solution for children ≤ 50 kg; 2 mg tablet for children > 50 kg) once daily for 8 weeks
Number of subjects: 213
Study 25239590 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 213
Study 25239590 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 213
Study 25239590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 22797101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100
Study 22797101 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 100
Study 20141583 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extracts, 3 capsules of 1 g per capsule daily
Number of subjects: 32
Study 20141583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17215475 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 17215475 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 16131622 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study 16131622 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 16131622 — intervention group
Group type: COMPARATOR
Intervention: Unrelated control
Number of subjects: 0
Study 11669594 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: short-term intra-arterial infusion of 550 mg/m² 5-FU (days 1-4) plus 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 5)
Number of subjects: 103
Study 11669594 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: continuous circadian intra-arterial infusion of 1400 mg/m² 5-FU plus 60 mg/m² i.v. leucovorin and 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 3)
Number of subjects: 103
Study 9209730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine serum level 50-150 ng/mL
Number of subjects: 50
Study 9209730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine serum level 200-300 ng/mL
Number of subjects: 50
Study 9209730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine serum level 350-450 ng/mL
Number of subjects: 50
Study 9209730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (general)
Number of subjects: 50
Study 10155067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular sheath access
Number of subjects: 200
Study 10155067 — intervention group
Group type: COMPARATOR
Intervention: Guidewire access
Number of subjects: 200
Study 2885173 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 119
Study 2885173 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam
Number of subjects: 119
Study 2142921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin (500 micrograms thrice daily for 10 days, then intranasal)
Number of subjects: 42
Study 2142921 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous goserelin
Number of subjects: 42
Study 1096120 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 2
Study 1096120 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study 31845172 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic procedure (group A)
Number of subjects: 112
Study 31845172 — intervention group
Group type: COMPARATOR
Intervention: Decompressive craniectomy (group B)
Number of subjects: 112
Study 31482268 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)
Number of subjects: 94
Study 31482268 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 94
Study 29149428 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string approximation (PSA)
Number of subjects: 61
Study 29149428 — intervention group
Group type: COMPARATOR
Intervention: Linear closure (PLC)
Number of subjects: 61
Study 25078981 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinaldehyde-based cream (RA-cream) applied once daily for 3 months
Number of subjects: 29
Study 25078981 — intervention group
Group type: COMPARATOR
Intervention: Control cream applied once daily for 3 months
Number of subjects: 29
Study 23570536 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide campaign (CWC) promoting physical activity from 2009 to 2010, comprising information, education, and support delivery.
Number of subjects: 6000
Study 23570536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 6000
Study 21846989 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC) within 72 hours
Number of subjects: 96
Study 21846989 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC) in 6-8 weeks
Number of subjects: 96
Study 21846989 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of bactobilia
Number of subjects: 96
Study 21846989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactobilia
Number of subjects: 96
Study 19583831 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 HZ excitatory rTMS to PMd
Number of subjects: 0
Study 19583831 — intervention group
Group type: COMPARATOR
Intervention: 1 HZ inhibitory rTMS to PMd
Number of subjects: 0
Study 19583831 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 16620353 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 56
Study 16620353 — intervention group
Group type: COMPARATOR
Intervention: Combination of ipratropium bromide and salbutamol sulphate
Number of subjects: 56
Study 14960129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 or 20mg
Number of subjects: 0
Study 14960129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5-20mg
Number of subjects: 0
Study 11520010 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exposure flights (1 test flight + 4 exposure flights)
Number of subjects: 30
Study 11520010 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (1 test flight + lengthy relaxation session)
Number of subjects: 30